Internal Medicine

A post-hoc analysis of clinical trial data found that psoriasis patients who were younger, less obese and had less severe psoriasis were more likely to achieve super-response to biologic treatment with guselkumab.

26 weeks of treatment with empagliflozin reduced the myocardial glucose metabolic rate by 45.1% in patients with type 2 diabetes.

A total of 178 patients achieved inactive disease while continuing adalimumab, and 51 patients maintained remission after discontinuing adalimumab.

Biologic agents may reduce the risk of mental health disorders among patients with moderate-to-severe psoriasis who discontinued treatment with conventional systemic agents, researchers in Canada found.

Data from this phase 2 study revealed that the efficacy and safety results support the continued investigation of mitapivat as treatment for adults with either α- or β-thalassemia who are not dependent on transfusions.

New data on the incidence of glaucoma among rural subjects ≥40 years old in China report a 0.4% annual rate.

Both a higher self-reported water intake and a greater measured 24-h urine volume were tied to an increased DED prevalence.

New phase 3 ENHANCE-2 data support a potential submission by Verona Pharma to the FDA.

In October, a new ICD-10-CM diagnosis code will be activated for APDS, a rare primary immunodeficiency disease, which will enable physicians and payers to add the diagnosis to patient charts for the first time in the US.

Study data show 14% of eyes managed with intravitreal therapy in routine clinical care experienced ≥ 10 letter loss.

Investigators believe these results could help improve disease recognition and diagnosis while supporting development of personalized prevention and therapy.

Dr. David Hudesman expects drug developers to continue to target biologics for the treatment of IBD.

Repeated metabolite monitoring with subsequent dose optimization resulted in 67.2% of patients achieving therapeutic levels after 1 year and 87.8% of patients achieving steroid-free remission, while 90% had no therapy escalation or surgery.

Prior to the launch of FSR's webinar on pulmonary sarcoidosis, Mary McGowan, CEO, discusses the private listening session held with the FDA that addressed the critical needs in the field.

Patients treated with LAIAs had a lower risk of hospitalization for any cause, hospitalizations for psychiatric disorders, hospitalizations for schizophrenia, and incident suicide attempts compared to patients treated with oral antipsychotics.

The indication to Arcutis makes the once-daily topical cream the first marketed PDE4 inhibitor of its kind.

The goal for many is to eradicate HCV by the year 2030.

The only adverse event identified was mild nausea for a duration of 10-21 days.

The American College of Physicians (ACP) aimed to inform on the ethical decision making regarding the integration of precision medicine and genetic testing into clinical care.

Jennifer Green, MD, discusses the benefit of relatively new innovations including continuous glucose monitoring and smart insulin pens.

Though current use rates have declined since 2017, investigators believe more young adults are transitioning from experimental to habitual use.

The Duke expert reviews key strategies for starting and continuing care with the pivotal glycemic control agent.

Dr. Patrick Flume encourages clinicians to think a little differently when presented with a patient who has a chronic cough without an identifiable cause.

Dr. John Botson explains that gout is not a patient problem, it's a disease problem, and it needs to be approached as a lifelong rheumatic disease as opposed to an episodic one.

More than 60% of faricimab patients could be treated every 4 months at 2-year mark of TENAYA and LUCERNE studies.

The phase 3 data presented at the ISTH 2022 Annual Congress show an 86% reduction of treated bleeds in patients with hemophilia A or B with inhibitors.

Bronchiectasis varies in presentation and appears to affect individuals from broad areas of the country. According to Dr. Patrick Flume, the task is to figure out what the best method of management is.

An assessment of anti-VEGF dose regimen strategies concludes with little difference in outcomes among treatment arms at 2 years.

The latest EUA, for two-dose NVX-CoV2373, introduces a protein-based adjuvant vaccine to the COVID-19 prevention market.

Nonmetropolitan counties have a lower density of ophthalmologists compared to metropolitan counties.